5 Best Performing Biotech ETFs in 2024

2. Franklin Genomic Advancements ETF (BATS:HELX)

5-Year Share Price Performance as of April 20: 20.61%

The Franklin Genomic Advancements ETF (BATS:HELX) is an actively managed ETF focused on capital appreciation by investing in companies involved in genomic-based technologies, aiming to enhance the quality of life. It targets firms benefiting from or facilitating advancements such as DNA sequencing, gene editing, and personalized medicine. As of April 19, the Franklin Genomic Advancements ETF (BATS:HELX) possesses $8.85 million in net assets.

Leading the portfolio of the Franklin Genomic Advancements ETF (BATS:HELX) is Medpace Holdings, Inc. (NASDAQ:MEDP). Medpace Holdings, Inc. (NASDAQ:MEDP) provides clinical research-based drug and medical device development services worldwide. On February 12, the company reported a Q4 GAAP EPS of $2.46 and revenue of $498.4 million, surpassing Wall Street estimates by $0.24 and $0.63 million, respectively.

Insider Monkey’s fourth-quarter database reveals that 38 hedge funds were bullish on Medpace Holdings, Inc. (NASDAQ:MEDP), up from 36 funds in the previous quarter.